Using NIR to Move Bioprocessing into a PAT Framework - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Using NIR to Move Bioprocessing into a PAT Framework
The author provides a review of PAT and tools such as near infrared analysis that may facilitate the use of PAT in the biopharmaceutical sector.

Pharmaceutical Technology
Volume 33, Issue 7


PAT is a useful paradigm and is making inroads into the biopharmaceutical industry, but the speed of acceptance has lagged behind other industries, including typical pharmaceuticals. This delay in acceptance is unfortunate because PAT initiatives, which are designed to develop a deeper understanding of the process and to control variability, could benefit biopharmaceuticals more than any other industry because biological systems are so inherently variable. NIR and other analytical tools required for this process understanding and variability control are already in place in other industries and will fit very well in all stages of biopharmaceutical manufacture. FDA encourages the use of these tools in a well-designed PAT process, and their use will reduce the time of manufacture and costs of reprocessed or out-of-specification product.

Todd Strother, PhD, is an applications scientist in the Scientific Instruments Division, Analyzer Group, at Thermo Fisher Scientific, 5225-4 Verona Road, Madison WI 53711, tel. 608.276.5626,


1. FDA, Guidance for Industry PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (Rockville, MD, Sept. 2004),

2. H. Trautman, "PAT in Bioprocessing," BioWorld EUROPE, 6–9 (2005).

3. J. Ganguly and G. Vogel, "Process Analytical Technology (PAT) and Scalable Automation for Bioprocess Control and Monitoring—A Case Study," Pharm. Engin., 26 (1), 1–9 (2006).

4. "Slow Adoption of PAT for Bioprocessing," Gen. Eng. & Biotechnol. News, 26 (16), (Sept. 15, 2006).

5. FDA, Center for Biologics Evaluation and Research Current Licensed Establishments and Products (Rockville, MD), Feb. 28, 2009,, accessed April 8, 2009.

6. D.L. Fernandes, "Biopharmaceutical Sialylation," Euro. Biopharm. Rev., Spring, 100–104 (2006).

7. J.A. Lopes et al., "Chemometrics in Bioprocess Engineering: Process Analytical Technology (PAT) Applications," Chemomet. and Intell. Lab. Systems, 74 (2), 269–275 (2004).

8. Y. Ozaki and T. Amari, "Near-Infrared Spectroscopy in Chemical Process Analysis," in Spectroscopy in Process Analysis, J. Chalmers, Ed. (Sheffield Academic Press, 2000), pp. 53–92.

9. C. Card et al., "Near-Infrared Spectroscopy for Rapid, Simultaneous Monitoring of Multiple Components in Mammalian Cell Culture," BioProcess Inter., 6 (3), 58–67 (2008).

10. P. Roychoudhury et al., "Multiplexing Fibre Optic Near Infrared (NIR) Spectroscopy as an Emerging Technology to Monitor Industrial Bioproceses," Analytica Chimica Acta, 590 (1), 110–117 (2007).

11. J. Hirsch, "Near-Infrared Analysis of Critical Parameters in Lyophilized Materials," BioPharm Inter., 19 (2), 32–36 (2006).

12. T.P. Lin and C.C. Hsu, "Determination of Residual Moisture in Lyophilized Protein Pharmaceuticals using a Rapid and Non-invasive Method: Near Infrared Spectroscopy," J. Pharm. Sci. Technol. 56 (4), 196–205 (2002).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here